Emerging therapies for multiple sclerosis

Abstract

Multiple sclerosis (MS) is a complex, chronic, and often disabling neurological disease, and MS affects more than 2.1 million people worldwide. Since the first MS drug was approved by the U.S. Food and Drug Administration (FDA) specially to treat RRMS in 1993, 12 approved DMAs emerged from years in the world. Health care professionals should evaluate cost-effectiveness of the therapies to determine the treatment option that best fits the needs and preferences of individual patients.